Friends or Foes: Matrix Metalloproteinases and Their Multifaceted Roles in Neurodegenerative Diseases
Open accessThe DOI matches its Crossref record; 307 of the 310 references it cites were found in a registry or an index.
Abstract
Neurodegeneration is a chronic progressive loss of neuronal cells leading to deterioration of central nervous system (CNS) functionality. It has been shown that neuroinflammation precedes neurodegeneration in various neurodegenerative diseases. Matrix metalloproteinases (MMPs), a protein family of zinc‐containing endopeptidases, are essential in (neuro)inflammation and might be involved in neurodegeneration. Although MMPs are indispensable for physiological development and functioning of the organism, they are often referred to as double‐edged swords due to their ability to also inflict substantial damage in various pathological conditions. MMP activity is strictly controlled, and its dysregulation leads to a variety of pathologies. Investigation of their potential use as therapeutic targets requires a better understanding of their contributions to the development of neurodegenerative diseases. Here, we review MMPs and their roles in neurodegenerative diseases: Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), Huntington’s disease (HD), and multiple sclerosis (MS). We also discuss MMP inhibition as a possible therapeutic strategy to treat neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“MMP-1, cleaves the structural connective tissue components collagen type I, II and II, and is detected only at low levels under physiological conditions, but can be abnormally high in several age-associated pathologies”
From Redox control of senescence and age-related disease. (2017) · cites this paper as [137]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the association between MMP-1 and ROS and the significance of these interactions in degenerative disease etiology is well established”
From Redox control of senescence and age-related disease. (2017) · cites this paper as [137]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–307 of 307
The dual personalities of matrix metalloproteinases in inflammation
Le, N. (2007) · Frontiers in Bioscience · doi:10.2741/2161 · Cited by 141 · cited 1×
“Ultimately, MMP cleavage of chemokines and cytokines can lead to either pro- or anti-inflammatory processes [18].”
BackgroundAdair, J. C., Charlie, J., Dencoff, J. E., Kaye, J. A., Quinn, J. F., Camicioli, R. M., Stetler-Stevenson, W. G., & Rosenberg, G. A. (2004) · Stroke · doi:10.1161/01.str.0000127420.10990.76 · Cited by 141 · cited 1×
“Intriguingly, patients with vascular dementia have been noted to have higher levels of MMP-9 in CSF even compared to patients suffering from AD [277].”
ResultMMP9: A novel function in synaptic plasticity
Dziembowska, M., & Włodarczyk, J. (2012) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2012.01.023 · Cited by 139 · cited 1×
“MMPs are essential for brain development due to their association with important neurophysiological functions, such as synaptic plasticity [2, 3] and long-term potentiation [4, 5].”
BackgroundNatural history of multiple sclerosis: risk factors and prognostic indicators
Vukusic, S., & Confavreux, C. (2007) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32812583ad · Cited by 138
Larsen, P. H., DaSilva, A. G., Conant, K., & Yong, V. W. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1880-05.2006 · Cited by 138
Kiaei, M., KIPIANI, K., Calingasan, N. Y., Wille, E. J., CHEN, J., Heissig, B., Rafii, S., Lorenzl, S., & Beal, M. F. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.01.036 · Cited by 137
Proteolysis of Aβ Peptide from Alzheimer Disease Brain by Gelatinase A
Roher, A. E., Kasunic, T. C., Woods, A. S., Cotter, R. J., Ball, M. J., & Fridman, R. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.2872 · Cited by 136
Matrix metalloproteinase-9 is elevated in serum of patients with amyotrophic lateral sclerosis
Beuche, W., Yushchenko, M., Mäder, M., Maliszewska, M., Felgenhauer, K., & Weber, F. (2000) · NeuroReport · doi:10.1097/00001756-200011090-00003 · Cited by 134
Park, S., Kim, K., Page, G. P., Allison, D. B., Weindruch, R., & Prolla, T. A. (2009) · Aging Cell · doi:10.1111/j.1474-9726.2009.00496.x · Cited by 134
Microglial activation in early stages of amyloid β protein deposition
Sasaki, A., Yamaguchi, H., Ogawa, A., Sugihara, S., & Nakazato, Y. (1997) · Acta Neuropathologica · doi:10.1007/s004010050713 · Cited by 132
Benseny‐Cases, N., Cócera, M., & Cladera, J. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.07.082 · Cited by 130
Asahina, M., Yoshiyama, Y., & Hattori, T. (2001) · PubMed · Cited by 129
Effective treatment of models of multiple sclerosis by matrix metalloproteinase inhibitors
Liedtke, W., Cannella, B., Mazzaccaro, R. J., Clements, J. M., Miller, K. M., Wucherpfenning, K. W., Gearing, A. J. H., & Raine, C. S. (1998) · Annals of Neurology · doi:10.1002/ana.410440110 · Cited by 129
A novel intracellular role of matrix metalloproteinase‐3 during apoptosis of dopaminergic cells
Choi, D. H., Kim, E., Son, H. J., Joh, T. H., Kim, Y. S., Kim, D., Flint Beal, M., & Hwang, O. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05399.x · Cited by 124 · cited 2×
“However, when cells were exposed to a selective MMP-3 inhibitor, NNGH (N-isobutyl-N-[4methoxyphenylsulfonyl]-glycylhydroxamic acid), cell survival was extended via the decrease of TNF-α release from activated microglial cells [51].”
BackgroundMatrix Metalloproteinases in the Neocortex and Spinal Cord of Amyotrophic Lateral Sclerosis Patients
Lim, G. P., Backstrom, J. R., Cullen, M. J., Miller, C. A., Atkinson, R. D., & Tökés, Z. A. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.67010251.x · Cited by 124 · cited 2×
“Abnormally high levels of MMP-9 and possible degradation of the matrix components contribute to ALS progression [236].”
Backgroundα-Lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis
Morini, M., Roccatagliata, L., Dell’Eva, R., Pedemonte, E., Furlan, R., Minghelli, S., Giunti, D., Pfeffer, U., Marchese, M., Noonan, D. M., et al. (2004) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2003.11.021 · Cited by 124
Halliday, M. R., Pomara, N., Sagare, A. P., Mack, W. J., Frangione, B., & Zlokovic, B. V. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.3841 · Cited by 119 · cited 2×
“The group of Zlokovic reported that, both in transgenic mice and in humans, APOE ε4 leads to BBB breakdown by activating the proinflammatory cyclophilin A (CypA)/MMP-9 pathway in brain pericytes, which are important components of the neurovascular unit and guardians of BBB integrity [61, 174].”
BackgroundDeposits of IgG and C3 in the spinal cord and motor cortex of ALS patients
Donnenfeld, H., Kascsak, R. J., & Bartfeld, H. (1984) · Journal of Neuroimmunology · doi:10.1016/0165-5728(84)90042-0 · Cited by 119 · cited 1×
“Since BSCB disruption in ALS [237–239] is accompanied by downregulation of mRNA for tight junction proteins [240], Miyazaki et al.”
BackgroundMorgan, L., Shah, B., Rivers, L. E., Barden, L., Groom, A. J., Chung, R., Higazi, D., Desmond, H., Smith, T., & Staddon, J. M. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2007.04.051 · Cited by 118
Alzheimer disease and neuroinflammation
McGeer, P. L., McGeer, E. G., & Yasojima, K. (2000) · Springer eBooks · doi:10.1007/978-3-7091-6781-6_8 · Cited by 118 · cited 1×
“Their notion is that activated microglia produce large amounts of inflammatory cytokines and chemokines, which sustain a chronic inflammation in the brain that ultimately leads to neuronal cell death [165].”
BackgroundA therapeutic role for matrix metalloproteinase inhibitors in lung diseases?
Vandenbroucke, R. E., Dejonckheere, E., & Libert, C. (2011) · European Respiratory Journal · doi:10.1183/09031936.00027411 · Cited by 118 · cited 1×
“MMP inhibitors yielded beneficial results in animal studies of lung inflammatory diseases [282], multiple sclerosis [265], meningitis [283–285], vascular dementia [52], stroke [286], acute cerebral ischemia [287, 288], and sepsis [1, 15, 289, 290].”
Self-citationBancher, C., & Jellinger, K. A. (1994) · Acta Neuropathologica · doi:10.1007/bf00296494 · Cited by 118 · cited 1×
“Cases of dementia with abundance of NFTs and a few amyloid plaques have been classified as a nonspecific type of neurodegenerative disorders, called NFT dementia [161].”
BackgroundInflammasome-Derived IL-1β Regulates the Production of GM-CSF by CD4+ T Cells and γδ T Cells
Lukens, J. R., Barr, M. J., Chaplin, D. D., Chi, H., & Kanneganti, T.-D. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103308 · Cited by 117
Neuroinflamm-Aging and Neurodegenerative Diseases: An Overview
Pizza, V., Agresta, A., W. D'Acunto, C., Festa, M., & Capasso, A. (2011) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152711796235014 · Cited by 117 · cited 1×
“Lowlevel systemic inflammation during aging has also been linked to the presence of active microglia and increased proinflammatory cytokines levels in the brain [132–134].”
BackgroundVandenbroucke, R. E., Dejonckheere, E., Van Lint, P., Demeestere, D., Van Wonterghem, E., Vanlaere, I., Puimege, L., Van Hauwermeiren, F., De Rycke, R., Mc Guire, C., et al. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.0967-12.2012 · Cited by 115 · cited 1×
“MMP inhibitors yielded beneficial results in animal studies of lung inflammatory diseases [282], multiple sclerosis [265], meningitis [283–285], vascular dementia [52], stroke [286], acute cerebral ischemia [287, 288], and sepsis [1, 15, 289, 290].”
Self-citationInsights into Alzheimer disease pathogenesis from studies in transgenic animal models
Schaeffer, E. L., Figueiró, M., & Gattaz, W. F. (2011) · Clinics · doi:10.1590/s1807-59322011001300006 · Cited by 114 · cited 1×
“Amyloid plaques, also called senile plaques, appear in brain parenchyma as extracellular deposits consisting of Aβ fibrils of 37–43 amino acids, originating from alternative processing of APP protein [144].”
BackgroundIshizuya-Oka, A., Li, Q., Amano, T., Damjanovski, S., Ueda, S., & Shi, Y.-B. (2000) · The Journal of Cell Biology · doi:10.1083/jcb.150.5.1177 · Cited by 113 · cited 1×
“The proposed mechanism of MMP action is via degradation of the ECM, since MMPs have an established role in the apoptosis of different cell types by the same mechanism [270].”
BackgroundPro-inflammatory effects of matrix metalloproteinase 7 in acute inflammation
Vandenbroucke, R. E., Vanlaere, I., Hauwermeiren, F. V., Wonterghem, E. V., Wilson, C. L., & Libert, C. (2013) · Mucosal Immunology · doi:10.1038/mi.2013.76 · Cited by 112 · cited 1×
“MMP inhibitors yielded beneficial results in animal studies of lung inflammatory diseases [282], multiple sclerosis [265], meningitis [283–285], vascular dementia [52], stroke [286], acute cerebral ischemia [287, 288], and sepsis [1, 15, 289, 290].”
Self-citationSang, Q. A., Jin, Y., Newcomer, R., Monroe, S., Fang, X., Hurst, D. R., Lee, S., Cao, Q., & Schwartz, M. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606776287045 · Cited by 112
Gasche, Y. (2006) · Frontiers in Bioscience · doi:10.2741/1883 · Cited by 111 · cited 1×
“It has been observed that MMPs in the CNS are secreted by microglia, astrocytes, and neurons [24].”
BackgroundHorstmann, S., Budig, L., Gardner, H., Koziol, J., Deuschle, M., Schilling, C., & Wagner, S. (2010) · International Psychogeriatrics · doi:10.1017/s1041610210000827 · Cited by 110
Aging, Amyloid, and Alzheimer's Disease: A Perspective in Honor of Carl Cotman
Selkoe, D. J. (2003) · Neurochemical Research · doi:10.1023/a:1026065122854 · Cited by 110
The Declining Infrastructure of the Aging Brain
Salat, D. H. (2011) · Brain Connectivity · doi:10.1089/brain.2011.0056 · Cited by 105 · cited 1×
“and/or contribute to aging and to some of the age-related diseases, such as AD [137, 138].”
BackgroundFluids and barriers of the CNS: a historical viewpoint
Liddelow, S. A. (2011) · Fluids and Barriers of the CNS · doi:10.1186/2045-8118-8-2 · Cited by 99 · cited 4×
“One of the theories suggests that BBB and BSCB breakdown could contribute to the motor neuron damage, due to the importance of these barriers in maintenance of homeostasis in the CNS. Indications of the involvement of MMPs, key players in barrier alteration, come from early studies on neocortex and spinal cord of ALS…”
BackgroundInfluentialModeling neuroinflammatory pathogenesis of Parkinson’s disease
Barnum, C. J., & Tansey, M. G. (2010) · Progress in brain research · doi:10.1016/s0079-6123(10)84006-3 · Cited by 99 · cited 1×
“The same effect was seen in the substantia nigra and striatum in animal models of PD based on MPTP injection [199–202].”
BackgroundEnzyme-replacement therapy for metabolic storage disorders
Brady, R. O., & Schiffmann, R. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00938-x · Cited by 99
Increased α-synuclein aggregation following limited cleavage by certain matrix metalloproteinases
Levin, J., Giese, A., Boetzel, K., Israel, L., Högen, T., Nübling, G., Kretzschmar, H. A., & Lorenzl, S. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2008.10.010 · Cited by 97 · cited 1×
“further studied the MMPspecific α-synuclein cleavage and showed that both MMP1 and MMP-3 mediate increased α-synuclein aggregation in comparison to trypsin and proteinase K [228].”
BackgroundAlzheimer's disease: β‐amyloid plaque formation in human brain
Seeman, P., & Seeman, N. (2011) · Synapse · doi:10.1002/syn.20957 · Cited by 97
Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia
Lorenzl, S., Büerger, K., Hampel, H., & Beal, M. F. (2007) · International Psychogeriatrics · doi:10.1017/s1041610207005790 · Cited by 96 · cited 2×
“observed higher levels of MMP9 in serum of AD patients [54].”
BackgroundBrain matrix metalloproteinase 1 levels are elevated in Alzheimer's disease
Leake, A., Morris, C. M., & Whateley, J. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01418-x · Cited by 95 · cited 1×
“reported a notable increase in MMP-1 in brain of AD patients [42].”
BackgroundThe significance of tau and α-synuclein inclusions in neurodegenerative diseases
Goedert, M. (2001) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(00)00200-8 · Cited by 95
Mizoguchi, H., Takuma, K., Fukuzaki, E., Ibi, D., Someya, E., Akazawa, K.-H., Alkam, T., Tsunekawa, H., Mouri, A., Noda, Y., et al. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.154724 · Cited by 95 · cited 1×
“related this increase to Aβ-induced cognitive impairment, and confirmed the results using MMP inhibitors and MMP9 knockout mice [59].”
ResultNuttall, R. K., Silva, C., Hader, W., Bar‐Or, A., Patel, K. D., Edwards, D. R., & Yong, V. W. (2007) · Glia · doi:10.1002/glia.20478 · Cited by 94
Liao, M.-C., & Van Nostrand, W. E. (2010) · Biochemistry · doi:10.1021/bi901994d · Cited by 92 · cited 1×
“In a transgenic mouse model of AD, expression of MMP-2 and MT1-MMP, a potent MMP-2 activator, was found in reactive astrocytes around amyloid plaques [45], and higher levels of Aβ 1–42 increased the production of MMP3, MMP-12, and MMP-13 in microglia [47].”
Niebroj‐Dobosz, I., Janik, P., Sokołowska, B., & Kwiecinski, H. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02775.x · Cited by 92 · cited 1×
“reported that in mild cases of ALS, expressions of MT-MMP-1, MMP-2, MMP-9, and TIMP-1 are elevated in serum compared to CSF, where MT-MMP-1, MMP-2, and TIMP-1 were upregulated or unchanged while MMP-9 levels were decreased [75].”
BackgroundA Biochemical Model of Matrix Metalloproteinase 9 Activation and Inhibition
Vempati, P., Karagiannis, E. D., & Popel, A. S. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m611500200 · Cited by 90 · cited 1×
“On the level of MMP-zymogen activation, mostly serine proteases and other MMPs are involved in initiating proteolytic cleavage of the prodomain; for example, MMP-3 can cleave pro-MMP-9 [22].”
BackgroundIto, S., Kimura, K., Haneda, M., Ishida, Y., Sawada, M., & Isobe, K. (2007) · Experimental Gerontology · doi:10.1016/j.exger.2006.11.012 · Cited by 90
Microglia can be induced by IFN-γ or IL-4 to express neural or dendritic-like markers
Butovsky, O., Bukshpan, S., Kunis, G., Jung, S., & Schwartz, M. (2007) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2007.04.009 · Cited by 90 · cited 1×
“Besides, they start tomimic antigen presenting cells (APC), which are immune cells in the periphery, by upregulating major histocompatibility complex (MHC) class II and becoming phagocytic [111].”
BackgroundDemestre, M., Parkin-Smith, G. F., Petzold, A., & Pullen, A. H. (2004) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2004.09.015 · Cited by 86 · cited 1×
“Two separate groups found significant increases in both pro-MMP-9 and active MMP-9 in serum of ALS patients relative to healthy controls [242, 243].”
BackgroundA new angle on blood–CNS interfaces: A role for connexins?
De Bock, M., Vandenbroucke, R. E., Decrock, E., Culot, M., Cecchelli, R., & Leybaert, L. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.02.060 · Cited by 84 · cited 4×
“One of the theories suggests that BBB and BSCB breakdown could contribute to the motor neuron damage, due to the importance of these barriers in maintenance of homeostasis in the CNS. Indications of the involvement of MMPs, key players in barrier alteration, come from early studies on neocortex and spinal cord of ALS…”
BackgroundInfluentialSelf-citationMultiple sclerosis is primarily a neurodegenerative disease
Chaudhuri, A. (2013) · Journal of Neural Transmission · doi:10.1007/s00702-013-1080-3 · Cited by 83 · cited 1×
“Interestingly, certain case reports have noted patients suffering fromMS and ALS at the same time [251].”
Backgroundβ-Amyloid induces the production of active, matrix-degrading proteases in cultured rat astrocytes
Deb, S., Wenjun Zhang, J., & Gottschall, P. E. (2003) · Brain Research · doi:10.1016/s0006-8993(03)02344-8 · Cited by 81
PERESS, N., PERILLO, E. D., & ZUCKER, S. (1995) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199501000-00002 · Cited by 81 · cited 1×
“It is evident that deregulation of TIMPs also leads to progression of AD [294].”
BackgroundLoss of dopaminergic neurons in parkinsonism: possible role of reactive dopamine metabolites
Hastings, T. G., & Zigmond, M. J. (1997) · Springer eBooks · doi:10.1007/978-3-7091-6844-8_11 · Cited by 81 · cited 1×
“This could be explained by specific susceptibility of dopaminergic neurons to oxidative stress due to the presence of tyrosine hydroxylase and monoamine oxidase, which are ROS-generating enzymes, as well as excessive production of easily oxidized cytosolic dopamine [217, 218].”
BackgroundFrancis, J. W., Visger, J. R. V., Markelonis, G. J., & Oh, T. H. (1995) · Neurotoxicology and Teratology · doi:10.1016/0892-0362(94)00048-i · Cited by 79
Annese, V., Herrero, M. T., Pentima, M. D., Gómez, A., Lombardi, L., Ros, C. M. B., de Pablos, V., Fernández‐Villalba, E., & Stefano, M. E. D. (2014) · Brain Structure and Function · doi:10.1007/s00429-014-0718-8 · Cited by 79
Multiple sclerosis: elevated expression of matrix metalloproteinases in blood monocytes
Kouwenhoven, M. C. M., Özenci, V., Gomes, A., Yarilin, D. A., Giedraitis, V., Press, R., & Link, H. (2001) · Journal of Autoimmunity · doi:10.1006/jaut.2001.0505 · Cited by 78 · cited 1×
“They found that all except MMP-14 were upregulated [81].”
BackgroundLinking neuron and skin: Matrix metalloproteinases in amyotrophic lateral sclerosis (ALS)
Fang, L., Huber-Abel, F., Teuchert, M., Hendrich, C., Dorst, J., Schattauer, D., Zettlmeissel, H., Wlaschek, M., Scharffetter‐Kochanek, K., Tumani, H., et al. (2009) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.05.025 · Cited by 77 · cited 1×
“Nevertheless, MMP-2 showed a slow but progressive decrease with the development of the disease [71].”
BackgroundApolipoprotein E genotype in diverse neurodegenerative disorders
Schneider, J. A., Gearing, M., Robbins, R. S., De l'Aune, W., & Mirra, S. S. (1995) · Annals of Neurology · doi:10.1002/ana.410380122 · Cited by 76 · cited 1×
“Additionally, occurrence of Aβ pathology has been observed in several other neurodegenerative diseases, such as PD, Pick’s disease (PiD), progressive supranuclear palsy (PSP), and corticobasal degeneration [147], as well as in ALS [148].”
BackgroundGilli, F., Bertolotto, A., Sala, A., Hoffmann, F., Capobianco, M., Malucchi, S., Glass, T., Kappos, L., Lindberg, R. L. P., & Leppert, D. (2004) · Brain · doi:10.1093/brain/awh028 · Cited by 76
Demeestere, D., Libert, C., & Vandenbroucke, R. E. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.05.003 · Cited by 71
Self-citationAlzheimer disease pathology in amyotrophic lateral sclerosis
Bowser, R. P., & Hamilton, R. L. (2004) · Acta Neuropathologica · doi:10.1007/s00401-004-0843-1 · Cited by 71 · cited 2×
“Additionally, occurrence of Aβ pathology has been observed in several other neurodegenerative diseases, such as PD, Pick’s disease (PiD), progressive supranuclear palsy (PSP), and corticobasal degeneration [147], as well as in ALS [148].”
BackgroundLorenzl, S., Calingasan, N. Y., Yang, L., Albers, D. S., Shugama, S., Gregorio, J., Krell, H. W., Chirichigno, J. W., JOH, T. H., & Beal, M. F. (2004) · NeuroMolecular Medicine · doi:10.1385/nmm:5:2:119 · Cited by 69
Microglial proliferation in the spinal cord of aged rats with a sciatic nerve injury
Stuesse, S. L., Cruce, W. L. R., Lovell, J. A., McBurney, D. L., & Crisp, T. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01142-3 · Cited by 68 · cited 1×
“Physiological aging is associated with a progressive increase in the number of activated microglial cells in the brain and spinal cord [126–128] accompanied by transition from normal microglial morphology to microglial dystrophy [129].”
BackgroundLiechti, F. D., Grandgirard, D., Leppert, D., & Leib, S. L. (2014) · Infection and Immunity · doi:10.1128/iai.00073-14 · Cited by 66 · cited 1×
“MMP inhibitors yielded beneficial results in animal studies of lung inflammatory diseases [282], multiple sclerosis [265], meningitis [283–285], vascular dementia [52], stroke [286], acute cerebral ischemia [287, 288], and sepsis [1, 15, 289, 290].”
Garcia‐Alloza, M., Prada, C., Lattarulo, C., Fine, S., Borrelli, L. A., Betensky, R., Greenberg, S. M., Frosch, M. P., & Bacskai, B. J. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06096.x · Cited by 64
Graesser, D., Mahooti, S., Haas, T. L., Davis, S., Rb, C., & Madri, J. A. (1998) · PubMed · Cited by 64
Criteria for the neuropathological diagnosis of dementing disorders: routes out of the swamp?
Jellinger, K. A. (2009) · Acta Neuropathologica · doi:10.1007/s00401-008-0466-z · Cited by 60 · cited 1×
“Nowadays, with the increasing amount of molecular and genetic data and the continuing efforts to find other common characteristics of neurodegenerative diseases, questions have arisen about the distinction between these diseases, making their classification even more problematic [99–101].”
BackgroundRegulation of matrix metalloproteinase 2 by oligomeric amyloid β protein
Li, W., Poteet, E., Xie, L., Liu, R., Wen, Y., & Yang, S.-H. (2011) · Brain Research · doi:10.1016/j.brainres.2011.02.078 · Cited by 60
Association Studies of MMP-9 in Parkinson’s Disease and Amyotrophic Lateral Sclerosis
He, X., Zhang, L., Yao, X., Hu, J., Yu, L., Jia, H., An, R., Liu, Z., & Xu, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073777 · Cited by 59
Gorkiewicz, T., Balcerzyk, M., Kaczmarek, L., & Knapska, E. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00073 · Cited by 58 · cited 1×
“MMPs are essential for brain development due to their association with important neurophysiological functions, such as synaptic plasticity [2, 3] and long-term potentiation [4, 5].”
BackgroundMatrix Metalloproteinases and Their Multiple Roles in Alzheimer's Disease
Wang, X.-X., Tan, M.-S., Yu, J.-T., & Tan, L. (2014) · BioMed Research International · doi:10.1155/2014/908636 · Cited by 55
Matrix metalloproteinase-12 contributes to neuroinflammation in the aged brain
Liu, Y., Zhang, M., Hao, W., Mihaljevic, I., Liu, X., Xie, K., Walter, S., & Fassbender, K. C. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.10.015 · Cited by 54 · cited 1×
“This finding is linked to aggravation of neuroinflammation associated with aging via the induction of the migration of bone marrow derived microglia to the brain [141].”
BackgroundDuran‐Vilaregut, J., del Valle, J., Manich, G., Camins, A., Pallàs, M., Vilaplana, J., & Pelegrí, C. (2011) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2010.01157.x · Cited by 53 · cited 1×
“Other evidence for involvement of MMP-9 in HD comes from the 3-nitropropionic acid animal model of the disease [79].”
BackgroundMlekusch, R., & Humpel, C. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.09.043 · Cited by 49 · cited 1×
“In contrast, Mlekusch andHumpel observed downregulation of MMP-3 and MMP-2 in CSF of AD patients, but it should be noted that these patients had lower Aβ levels [175].”
BackgroundOn the ‘classification’ of neurodegenerative disorders: discrete entities, overlap or continuum?
Armstrong, R. A. (2012) · Folia Neuropathologica · doi:10.5114/fn.2012.30521 · Cited by 47 · cited 2×
“However, occurrence of TDP-43 is not characteristic of only ALS but was found in several patients with frontotemporal lobar degeneration with TDP proteinopathy (FTLD-TDP), as well as in frontotemporal dementia, AD, and some other neurodegenerative diseases [96].”
BackgroundAlzheimer’s Disease and Genetics of Inflammation: A Pharmacogenomic Vision
Vasto, S., Candore, G., Duro, G., Lio, D., Grimaldi, M. P., & Caruso, C. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.12.1735 · Cited by 46 · cited 1×
“As reported forMMP-9,MMP-3 candegradeAβ [47, 50, 176].”
Du, H., Li, P., Wang, J., Qing, X., & Li, W. (2011) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-011-9744-8 · Cited by 45
Langenfurth, A., Rinnenthal, J. L., Vinnakota, K., Prinz, V., Carlo, A., Stadelmann, C., Siffrin, V., Peaschke, S., Endres, M., Heppner, F., et al. (2014) · Journal of Neuroscience Research · doi:10.1002/jnr.23288 · Cited by 44 · cited 1×
“found upregulated microglial/macrophage expression in tissues from AD patients, as well as in a mouse model of AD [178].”
BackgroundNorga, K., Paemen, L. R., Masure, S., Dillen, C., Heremans, H., Billiau, A., Carton, H., Cuzner, L., Olsson, T. P., Damme, J. V., et al. (1995) · Inflammation Research · doi:10.1007/bf01757357 · Cited by 41
Smith, M. E., & Amaducci, L. A. (1982) · Neurochemical Research · doi:10.1007/bf00965121 · Cited by 38 · cited 1×
“There are several reports on the use of synthetic MMP inhibitors to ameliorate the symptoms of EAE, and protease inhibitors were used to treat EAE as early as 1982 [295].”
BackgroundAssociation of matrix metalloproteinases with MRI indices of brain ischemia and aging
Romero, J. R., Vasan, R. S., Beiser, A., Au, R., Benjamin, E. J., DeCarli, C. S., Wolf, P. A., & Seshadri, S. S. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.11.004 · Cited by 38 · cited 1×
“found that upregulation of MMP-9 was associated with aging and circulating levels of MMP-9 and TIMP-1 in patients with brain ischemia and aging [140].”
BackgroundNeuroinflammation and the prospects for anti-inflammatory treatment of Parkinson's disease.
Whitton, P. S. (2010) · PubMed · Cited by 36
Armstrong, R. A., Cairns, N. J., & Lantos, P. L. (2000) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000017235 · Cited by 36 · cited 1×
“Although Aβ deposition is considered a signature lesion for AD, it also occurs in Down’s syndrome, possibly due to triple multiplication of amyloid precursor protein (APP), as well as in certain cases of dementia with Lewy bodies [145, 146].”
BackgroundPerl, D. P., & Pendlebury, W. W. (1986) · Neurologic Clinics · doi:10.1016/s0733-8619(18)30974-5 · Cited by 36 · cited 2×
“Nowadays, with the increasing amount of molecular and genetic data and the continuing efforts to find other common characteristics of neurodegenerative diseases, questions have arisen about the distinction between these diseases, making their classification even more problematic [99–101].”
BackgroundMolecular Pathology in Neurodegenerative Diseases
H. Peden, A., & W. Ironside, J. (2012) · Current Drug Targets · doi:10.2174/138945012803530134 · Cited by 35 · cited 1×
“It is also speculated that oxidative stress could be generated from dopaminergic metabolism, mitochondrial dysfunction, and microglial activation, which could be influenced beforehand by various toxins and mutations in Parkin, PINK1, DJ1, or HtrA1, which are important for physiological mitochondrial functioning [212].”
BackgroundDuPengtao, H., Wang, L., & Li, X. Q. (2012) · Cited by 34
Natural History of Multiple Sclerosis: Early Prognostic Factors
Mowry, E. M. (2011) · Neurologic Clinics · doi:10.1016/j.ncl.2011.01.001 · Cited by 31 · cited 1×
“At onset, RRMS is characterized as a neuroinflammatory state [248].”
BackgroundSoon, C. P. W., Crouch, P. J., Turner, B. J., McLean, C., Laughton, K. M., Atkin, J. D., Masters, C. L., White, A. R., & Li, Q.-X. (2010) · Neuromuscular Disorders · doi:10.1016/j.nmd.2009.11.015 · Cited by 28 · cited 1×
“Another group showed reducedMMP-9 activity during disease progression, with the peak at the onset of ALS, and described a similar profile for MMP-2 [74].”
BackgroundPark, C. H., Shin, T. K., Lee, H. Y., Kim, S. J., & Lee, W. S. (2011) · The Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2011.15.2.115 · Cited by 27 · cited 1×
“MMP inhibitors yielded beneficial results in animal studies of lung inflammatory diseases [282], multiple sclerosis [265], meningitis [283–285], vascular dementia [52], stroke [286], acute cerebral ischemia [287, 288], and sepsis [1, 15, 289, 290].”
Sokołowska, B., Jóźwik, A., Niebrój-Dobosz, I., Janik, P., & Kwieciński, H. (2009) · PubMed · Cited by 27
Althoff, G. E. M., Wolfer, D. P., Timmesfeld, N., Kanzler, B., Schrewe, H., & Pagenstecher, A. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090918 · Cited by 27
Saarela, M., Lehtimäki, T. J., Rinne, J. O., Hervonen, A., Jylhä, M. K., Röyttä, M., Ahonen, J.-P., & Mattila, K. M. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.06.027 · Cited by 23
Multiple brain pathologies in dementia are common
Woodward, M., Mackenzie, I. R., Hsiung, G. R., Jacova, C., & Feldman, H. (2010) · European Geriatric Medicine · doi:10.1016/j.eurger.2010.07.012 · Cited by 23 · cited 1×
“However, in certain cases diagnosis is difficult due to the coincidence of clinicopathological features of several neurodegenerative diseases [97–99].”
BackgroundMatrix metalloproteinases in multiple sclerosis
Bever, C. T., & Rosenberg, G. A. (1999) · Neurology · doi:10.1212/wnl.53.7.1380 · Cited by 23
Safciuc, F., Constantin, A. L., Manea, A., Nicolae, M., Popov, D., Raicu, M., Alexandru, D., & Constantinescu, E. (2007) · Current Neurovascular Research · doi:10.2174/156720207782446351 · Cited by 23 · cited 1×
“showed thatmicrovessels in the brain of aged rats exhibit decreased MMP-2 activity and appearance of MMP-9 [142].”
BackgroundLiechti, F. D., Bächtold, F., Grandgirard, D., Leppert, D., & Leib, S. L. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0257-0 · Cited by 22 · cited 1×
“MMP inhibitors yielded beneficial results in animal studies of lung inflammatory diseases [282], multiple sclerosis [265], meningitis [283–285], vascular dementia [52], stroke [286], acute cerebral ischemia [287, 288], and sepsis [1, 15, 289, 290].”
Die neuropathologische Diagnostik neurodegenerativer und demenzieller Krankheiten
Kretzschmar, H. A., & Neumann, M. (2000) · Der Pathologe · doi:10.1007/s002920000402 · Cited by 20
Dobrucki, L. W., Meoli, D. F., Hu, J., Sadeghi, M. M., & Sinusas, A. J. (2009) · PubMed · Cited by 16
Gelatinase A not alpha-secretase?
Walsh, D. M., Williams, C. H., KENNEDY, H. E., Allsop, D., & Murphy, G. (1994) · Nature · doi:10.1038/367027a0 · Cited by 15 · cited 1×
“However, whether MMP-2 can cleave APP remains debatable [291, 293].”
BackgroundMATRIX METALLOPROTEINASE PROFILE IN PATIENTS WITH CREUZTFELDT‐JAKOB DISEASE
Kettlun, A. M., Collados, L., García, L., Cartier, L., Wolf, M. E., Mosnaim, A. D., & Valenzuela, M. (2003) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2003.tb10536.x · Cited by 15 · cited 7×
“As far as therapeutic opportunities of MMP inhibition in PD are concerned, Lorenzl et al. reported the expression of MMPs such as MMP-1, MMP2, and MMP-9 and also TIMP-1 and TIMP-2 in substantia nigra of postmortem PD brain samples [63].”
BackgroundInfluentialMatrix Metalloproteinase-9, Its Tissue Inhibitor(TIMP)-1 and CRP in Alzheimer’s Disease
Inspector, M., Aharon‐Peretz, J., Glass‐Marmor, L., & Miller, A. (2005) · European Neurology · doi:10.1159/000086124 · Cited by 12 · cited 1×
“Finally, levels of TIMP-1 and C-reactive protein (CRP) were found to be increased in AD patients, and they decreased remarkably after treatment with acetylcholinesterase inhibitors (AchEIs), one of the few available therapies of AD [179].”
BackgroundEvidencias en favor de una pérdida axonal primaria en la esclerosis múltiple
Anthony, D. C., Hughes, P., & Perry, V. H. (2000) · Revista de Neurología · doi:10.33588/rn.3012.99548 · Cited by 10
Bancher, C., & Jellinger, K. A. (1994) · Acta Neuropathologica · doi:10.1007/s004010050200 · Cited by 3
Matěj, R., & Rusina, R. (2012) · PubMed · Cited by 2
Langston, J. W., Forno, L. S., Tetrud, J., Reeves, A. G., Kaplan, J. A., & Karluk, D. (1999) · Annals of Neurology · doi:10.1002/1531-8249(199910)46:4 · Cited by 1
(1999) · doi:10.1002/1531-8249(199912)46:6<860::aid-ana8>3.0.co;2-m
Research works printed but not linked: 4
- 10.1002/(sici)1097-4547(19981001)54:160;68::aid-jnr862;3.0.co;2-f · doi:10.1002/(sici)1097-4547(19981001)54:160;68::aid-jnr862;3.0.co;2-f
- 10.1002/1531-8249(199912)46:660;860::aid-ana862;3.0.co;2-m · doi:10.1002/1531-8249(199912)46:660;860::aid-ana862;3.0.co;2-m
- Goldenberg M. M., 2012, Multiple sclerosis review, P & T, 37, 175
- 10.1523/JNEUROSCI.0967-12.2012 · DOI · Paper page
Cited by
The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases
Cabral-Pacheco, G. A., Garza-Veloz, I., Castruita-De la Rosa, C., Ramirez-Acuña, J. M., Perez-Romero, B. A., Guerrero-Rodriguez, J. F., Martinez-Avila, N., & Martinez-Fierro, M. L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249739 · Cited by 1,820
“It has been shown that MMPs participate in a common pathway related to the pathological changes in CNS homeostasis, that is, the accumulation of pro-inflammatory molecules or aggregates of proteins and peptides, leading to the increased permeability of the CNS barrier and, therefore, to cell death [48].”
BackgroundInfluentialde Almeida, L. G. N., Thode, H., Eslambolchi, Y., Chopra, S., Young, D., Gill, S., Devel, L., & Dufour, A. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000349 · Cited by 535
Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing
Boland, B., Yu, W. H., Corti, O., Mollereau, B., Henriques, A., Bezard, E., Pastores, G. M., Rubinsztein, D. C., Nixon, R. A., Duchen, M. R., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.109 · Cited by 558
Chinta, S. J., Woods, G., Demaria, M., Rane, A., Zou, Y., McQuade, A., Rajagopalan, S., Limbad, C., Madden, D. T., Campisi, J., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2017.12.092 · Cited by 530
“, 2010); SASP factors have been shown to disrupt tissue structure and function (Brkic et al., 2015).”
BackgroundThe vascular basement membrane in the healthy and pathological brain
Thomsen, M. S., Routhe, L. J., & Moos, T. (2017) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x17722436 · Cited by 490
“MMPs, a family of zinc endopeptidases, are produced in a latent form and contain a pro-peptide responsible for maintaining the latent form of MMP and a hemopexin-like domain, which can be recognized by tissue inhibitor of metalloproteinases (TIMPs).(96) The activity of these protease systems is highly regulated and de…”
Background
Metadata
- Authors
- Brkic, M., Balusu, S., Libert, C., & Vandenbroucke, R. E.
- Affiliations
- Ghent University (BE)
- Corresponding author
- Vandenbroucke, Roosmarijn E.
- Venue
- Mediators of Inflammation
- Publisher
- Wiley
- Published
- 2015-01
- Volume
- 2015
- Issue
- 1
- Pages
- 620581-620581
- ISSN
- 0962-9351 (ISSN-L)
- 1466-1861
- PMC
- PMC4619970
- OpenAlex
- W2165521823
- Cited by
- 205
- References
- 310
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 19 · 2023: 12 · 2022: 24 · 2021: 36 · 2020: 28 · 2019: 13 · 2018: 24 · 2017: 22 · 2016: 8
- FWCI
- 1.75
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Mediators of Inflammation (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministry of Education, Science and Technological Development of the Republic of Serbia (ON173056)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- matrix metalloproteinases, neurodegenerative diseases, neuroinflammation, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, multiple sclerosis, matrix metalloproteinase inhibition, therapeutic target
- MeSH terms
- Alzheimer Disease, Amyotrophic Lateral Sclerosis, Animals, Humans, Huntington Disease, Inflammation, Multiple Sclerosis, Parkinson Disease, Biomarkers, Gene Expression Regulation, Enzymologic, Neurodegenerative Diseases, Matrix Metalloproteinases, Neurogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.